04-06-2024, 04:26 PM
The patient was a 59-year-old man with a 25-year history of T2D who developed end-stage diabetic nephropathy and underwent kidney transplantation in June of 2017 and displayed poor glycemic control since November of 2019, characterized by blood glucose level ranging from 3.66–14.60 mmol/L, mean amplitude of glycemic excursion (MAGE) of 5.54 mmol/L, the time-in-the-tight-target-range (TITR, 3.9–7.8 mM) of 56.7%, with daily hyperglycemic events (> 10.0 mmol/L) of 0.7/d and hypoglycemic events (< 3.9 mmol/L) of 0.3/d (Supplementary Table S1).
Due to the major concerns of hypoglycemia and the detrimental effect of poor glycemic control on the long-term survival of the donor kidney, the patient agreed to pursue transplantation with autologous E-islets.
https://www.nature.com/articles/s41421-024-00662-3
Due to the major concerns of hypoglycemia and the detrimental effect of poor glycemic control on the long-term survival of the donor kidney, the patient agreed to pursue transplantation with autologous E-islets.
https://www.nature.com/articles/s41421-024-00662-3